Serum Institute Of India To Start Manufacturing Sputnik V Vaccines From September

As per a statement by the Russian Direct Investment Fund (RDIF), Serum Institute of India (SII), based in Pune, is expected to commence manufacturing of Sputnik V COVID-19 vaccine from September.

The RDIF statement stated that the expected manufacturing is expected to result in ~300 million vaccine doses produced by SII per year.

The RDIF said, “SII has obtained vector and cell samples from the Gamaleya Centre, as part of the technical transfer process. The cultivation process has commenced post receiving import approvals by the Drug Controller General of India (DCGI).”

This development extends in the background of Dr. Reddy's (a Hyderabad-based pharmaceutical company), recently obtaining ~ 3 million Sputnik V doses from RDIF with which it has an agreement to offer doses to 125 million individuals (250 million vials) in India.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.